Methods of treating immune diseases by administering antibody polypeptides that antagonize cd40

A method of treating an immune disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of antibody polypeptide comprising a first variable domain, wherein said antibody polypeptide specifically binds human CD40, wherein the first variable domain comprises:

• (a) a CDR1 region comprising the amino acid sequence of the CDR1 region of BMS3h-56-269 (amino acids 31 to 35 of SEQ ID NO 417),
• (b) a CDR2 region comprising the amino acid sequence of the CDR2 region of BMS3h-56-269 (amino acids 50 to 66 of SEQ ID NO:
• 417), and
• (c) a CDR3 region comprising the amino acid sequence of the CDR3 region of BMS3h-56-269 (amino acids 99 to 105 of SEQ ID NO:
• 417),
• or
• the amino acid sequences of the CDR1, CDR2, and CDR3 regions are selected from amino acids 31 to 35, 50 to 66, and 99-105 respectively, of one of the antibody polypeptide sequences selected from the group consisting of:
• SEQ ID NO;
• 317;
• SEQ ID NQ:
• 318;
• SEQ ID NO:
• 320;
• SEQ ID NO:
• 321;
• SEQ ID NO:
• 324:
• SEQ ID NO:
• 325;
• SEQ ID NO:
• 326:
• SEQ ID NO:
• 327;
• SEQ ID NO:
• 331:
• SEQ ID NO:
• 332;
• SEQ ID NO:
• 333;
• SEQ ID NO:
• 334;
• SEQ ID NO:
• 335;
• SEQ ID NO:
• 336:
• SEQ ID NO:
• 337:
• SEQ ID NO:
• 341;
• SEQ ID NO:
• 342:
• SEQ ID NO:
• 343;
• SEQ ID NO:
• 344;
• SEQ ID NO;
• 345:
• SEQ ID NO:
• 346:
• SEQ ID NO:
• 347;
• SEQ ID NO:
• 348 SEQ ID NO:
• 349;
• SEQ ID NO:
• 350:
• SEQ ID NO:
• 353;
• SEQ ID NO:
• 355:
• SEQ ID NO:
• 356;
• SEQ ID NO:
• 358:
• SEQ ID NO:
• 366;
• SEQ ID NO:
• 367;
• SEQ ID NO:
• 376;
• SEQ ID NO:
• 379;
• SEQ ID NO:
• 381:
• SEQ ID NO:
• 386;
• SEQ ID NO:
• 394:
• SEQ ID NO:
• 403:
• SEQ ID NO:
• 405;
• SEQ ID NO:
• 412;
• and SEQ ID NO:
• 419.